A randomized, double-blind, placebo controlled, parallel group clinical study for the comparative evaluation of efficacy and tolerability of lutein and zeaxanthin (XanMax2002) in adult subjects with mild cognitive impairment (MCI) - NIL

Start Date05 Aug 2024

Sponsor / Collaborator

Katra Phytochem (India) Pvt Ltd.

CTRI/2023/11/060356 / Not yet recruitingPhase 3

A Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Efficacy of Supplementation of Lutein Formulations on Improving Macular Pigment Optical Density in Healthy Adults - Nil

Start Date11 Dec 2023

Sponsor / Collaborator

India Glycols Ltd.

CTRI/2022/12/048392 / Active, not recruitingPhase 4

Clinical study to evaluate the effect of Lutein & Zeaxanthin on Macular Pigment Optical Density and eye stress response – through protecting photoreceptor cell from the blue light effects- Prospective, 3 arm, 2 sequence, Placebo controlled, cross over, double blind, randomized study

Start Date30 Dec 2022

Sponsor / Collaborator-

100 Clinical Results associated with Lutein

100 Translational Medicine associated with Lutein

100 Patents (Medical) associated with Lutein

4,820

Literatures (Medical) associated with Lutein

01 Dec 2024·Applied Microbiology and Biotechnology

Unveiling the potential of Pseudococcomyxa simplex: a stepwise extraction for cosmetic applications

Article

Author: Annaz, Hassan ; Ibanez, Elena ; Imbimbo, Paola ; Ferrara, Alfonso ; Zarrelli, Armando ; Di Meo, Maria Chiara ; Alvarez-Rivera, Gerardo ; Monti, Daria Maria ; Giustino, Enrica

AbstractMicroalgae are gaining attention as they are considered green fabrics able to synthesize many bioactive metabolites, with unique biological activities. However, their use at an industrial scale is still a challenge because of the high costs related to upstream and downstream processes. Here, a biorefinery approach was proposed, starting from the biomass of the green microalga Pseudococcomyxa simplex for the extraction of two classes of molecules with a potential use in the cosmetic industry. Carotenoids were extracted first by an ultrasound-assisted extraction, and then, from the residual biomass, lipids were obtained by a conventional extraction. The chemical characterization of the ethanol extract indicated lutein, a biosynthetic derivative of α-carotene, as the most abundant carotenoid. The extract was found to be fully biocompatible on a cell-based model, active as antioxidant and with an in vitro anti-aging property. In particular, the lutein-enriched fraction was able to activate Nrf2 pathway, which plays a key role also in aging process. Finally, lipids were isolated from the residual biomass and the isolated fatty acids fraction was composed by palmitic and stearic acids. These molecules, fully biocompatible, can find application as emulsifiers and softener agents in cosmetic formulations. Thus, an untapped microalgal species can represent a sustainable source for cosmeceutical formulations.Key points• Pseudococcomyxa simplex has been explored in a cascade approach.• Lutein is the main extracted carotenoid and has antioxidant and anti-aging activity.• Fatty acids are mainly composed of palmitic and stearic acids.Graphical abstract

01 Dec 2024·Computational and Structural Biotechnology Journal

GhLCYε-3 characterized as a lycopene cyclase gene responding to drought stress in cotton

Article

Author: Lu, Xuke ; Zhao, Lanjie ; Fan, Yapeng ; Li, Shuyan ; Li, Fei ; He, Yunxin ; Wang, Junjuan ; Chen, Xiugui ; Huang, Hui ; Ye, Wuwei ; Zhang, Yuexin ; Wang, Shuai ; Ni, Kesong ; Guo, Lixue ; Cui, Ruifeng

Drought stress significantly affects crop productivity. Carotenoids are essential photosynthetic pigment for plants, bacteria, and algae, with signaling and antioxidant functions. Lutein is a crucial branch product in the carotenoid synthesis pathway, which effectively improves the stress tolerance of higher plants. lycopene cyclase, a central enzyme for lutein synthesis, holds great significance in regulating lutein production. This research establishes a correlation between lutein content and stress resistance by measuring the drought resistance and lutein content of various cotton materials. To identify which crucial genes are associated with lutein, the lycopene cyclase family (LCYs) was analyzed. The research found that LCYs form a highly conserved family divided into two subfamilies, LCY-ε (lycopene ε-cyclase) and LCY-β (lycopene β-cyclase). Most members of the LCY family contain photoresponsive elements and abscisic acid elements. qRT-PCR demonstrates showed that most genes responded positively to drought stress, and GhLCYε-3 was expressed significantly differently under drought stress. Virus-induced gene silencing (VIGS) assay showed that the content of GhLCYε-3 was significantly increased with MDA and PRO, and the contents of chlorophyll and lutein were significantly decreased in pYL156 plants. The decrease in GhLCYε-3 expression is speculated to lead to reduced lutein content in vivo, resulting in the accumulation of reactive oxygen species (ROS) and decreased drought tolerance. This research enriched the understanding of LCY gene family and lutein function, and provided a new reference for cotton planting in arid areas.SynopsisLycopene cyclase plays an important role in enhancing the ability of scavenging ROS and drought resistance of plants.

01 Nov 2024·Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology

Neurodevelopmental changes in Drosophila melanogaster are restored by treatment with lutein-loaded nanoparticles: Positive modulation of neurochemical and behavioral parameters

Article

Author: Gonçalves, Odinei Hess ; Fernandes, Eliana Jardim ; Janner, Dieniffer Espinosa ; Mustafa, Mustafa Munir Dahleh ; Guerra, Gustavo Petri ; de Freitas, Rilton Alves ; Musachio, Elize Aparecida Santos ; Meichtry, Luana Barreto ; Chaves, Nathalie Savedra Gomes ; De Carvalho, Amarilis Santos ; Prigol, Marina ; Poetini, Márcia Rósula ; Leimann, Fernanda Vitória

Neurodevelopmental disorders, such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), are characterized by persistent changes in communication and social interaction, as well as restricted and stereotyped patterns of behavior. The complex etiology of these disorders possibly combines the effects of multiple genes and environmental factors. Hence, exposure to insecticides such as imidacloprid (IMI) has been used to replicate the changes observed in these disorders. Lutein is known for its anti-inflammatory and antioxidant properties and is associated with neuroprotective effects. Therefore, the aim of this study was to evaluate the protective effect of lutein-loaded nanoparticles, along with their mechanisms of action, on Drosophila melanogaster offspring exposed to IMI-induced damage. To simulate the neurodevelopmental disorder model, flies were exposed to a diet containing IMI for 7 days. Posteriorly, their offspring were exposed to a diet containing lutein-loaded nanoparticles for a period of 24 h, and male and female flies were subjected to behavioral and biochemical evaluations. Treatment with lutein-loaded nanoparticles reversed the parameters of hyperactivity, aggressiveness, social interaction, repetitive movements, and anxiety in the offspring of flies exposed to IMI. It also protected markers of oxidative stress and cell viability, in addition to preventing the reduction of Nrf2 and Shank3 immunoreactivity. These results demonstrate that the damage induced by exposure to IMI was restored through treatment with lutein-loaded nanoparticles, elucidating lutein's mechanisms of action as a therapeutic agent, which, after further studies, can become a co-adjuvant in the treatment of neurodevelopmental disorders, such as ASD and ADHD.

News (Medical) associated with Lutein

16 Jul 2024

·www.drugs.com

Supplements Slow Disease Progression During Late Stage of "Dry" Age-Related Macular Degeneration

July 16, 2024 -- In a new analysis of data, researchers at the National Institutes of Health (NIH) have found that taking a daily supplement containing antioxidant vitamins and minerals slows progression of late-stage dry age-related macular degeneration (AMD), potentially helping people with late-stage disease preserve their central vision. Researchers reviewed the original retinal scans of participants in the Age-Related Eye Diseases Studies (AREDS and AREDS2) and found that, for people with late-stage dry AMD, taking the antioxidant supplement slowed expansion of geographic atrophy regions towards the central foveal region of the retina. The study was published in the journal Ophthalmology . “We’ve known for a long time that AREDS2 supplements help slow the progression from intermediate to late AMD. Our analysis shows that taking AREDS2 supplements can also slow disease progression in people with late dry AMD,” said Tiarnan Keenan, M.D., Ph.D., of NIH’s National Eye Institute (NEI) and lead author of the study. “These findings support the continued use of AREDS2 supplements by people with late dry AMD.” In their new analysis, the researchers reviewed the original retinal scans of participants in the AREDS (total 318 participants, 392 eyes) and AREDS2 (total 891 participants, 1210 eyes) trials who developed dry AMD, calculating the position and expansion rate of their regions of geographic atrophy. For those people who developed geographic atrophy in their central vision, the supplements had little benefit. But for the majority who developed geographic atrophy far from the fovea, the supplements slowed the rate of expansion towards the fovea by approximately 55% over an average of three years. In early and intermediate AMD, the light-sensing retina at the back of the eye develops small yellow deposits of fatty proteins called drusen. When the disease progresses to the late stage, people can develop leaky blood vessels (“wet” AMD) or can lose regions of light-sensitive cells in the retina (“dry” AMD). The geographic atrophy in these regions slowly expands over time, causing people to progressively lose their central vision. The original AREDS trial found that a supplement formula containing antioxidants (vitamin C, E, and beta-carotene), along with zinc and copper, could slow progression of intermediate to late-stage AMD. The subsequent AREDS2 trial found that substituting the antioxidants lutein and zeaxanthin for beta-carotene improved the efficacy of the supplement formula and eliminated certain risks. At the time, neither trial detected any further benefit once participants had developed late-stage disease. However, that original analysis did not account for a phenomenon in the dry form of late AMD called “foveal sparing.” While all regions of the retina are sensitive to light, the region that gives us the highest acuity central vision is called the fovea. Many people with dry AMD first develop geographic atrophy outside this foveal region, and they only lose their central vision when the geographic atrophy regions expand into the foveal area. “Our high acuity central vision is essential for tasks like reading and driving. Given that there are few therapeutic options for people with late-stage dry AMD to retain or restore their vision, antioxidant supplementation is a simple step that may slow central vision loss, even for those with late disease,” Keenan said. “We plan to confirm these findings in a dedicated clinical trial in the near future.” Learn more about AREDS and AREDS2 Study authors include Keenan, Elvira Agrón, and Emily Chew, M.D. from NEI, Pearse Keane, M.D. from Moorfields Eye Hospital, U.K., and Amitha Domalpally, M.D., Ph.D., University of Wisconsin-Madison. The research was supported by the NEI Intramural Research Program. Funding for the AREDS and AREDS2 studies, under contracts NOI-EY-0-2127, HHS-N-260-2005-00007-C and N01-EY-5-0007, were provided by NEI and the NIH Office of Dietary Supplements, the National Center for Complementary and Alternative Medicine, the National Institute on Aging, the National Heart, Lung, and Blood Institute, and the National Institute of Neurological Disorders and Stroke. The AREDS and AREDS2 studies, clinicaltrials.gov numbers NCT00000145 and NCT00345176, respectively, were conducted at the NIH Clinical Center. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

06 Mar 2024

·www.prnewswire.com

Puritan's Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands

NEW YORK, March 6, 2024 /PRNewswire/ -- As global health awareness has increased, there has been a notable shift in people's focus from "treatment" to "prevention" of diseases. On December 4, 2023, the International Self-Care Foundation and the Dietary Guidance Committee of the Chinese Aging Well Association (CAWA) jointly organized the 2023 China Nutrition and Health Industry High-Quality Development Conference. Renowned Chinese experts delivered thematic speeches and participated in panel discussions on nutrition and health issues. Throughout the conference, experts analyzed the current state of cardiovascular research and made predictions for the future of cardiovascular disease. Puritan's Pride™, a global brand, was honored with the Cardiovascular Health Outstanding Contribution Award during the event. In addition, its Coenzyme Q10 product line was recognized with the 2023 Dietary Guidance Committee of CAWA Recommended Product Award. Continue Reading Puritan’s Pride Steadily Expands Its Global Influence, Securing a Leading Position Among Nutritional Brands Puritan's Pride™ prioritizes providing high-quality nutritional diet services to all families. With a strong emphasis on health and nutrition, the company uses advanced scientific research and patented technologies to create products from high-quality, safe natural ingredients. It has established itself as one of the leading nutritional supplement brands, boasting a customer base of more than six million satisfied individuals. Puritan's Pride™ is the preferred choice for people seeking health supplements, excelling in both quality and affordability. Puritan's Pride™ is a leading health supplement company established in 1973 in Long Island, New York. It boasts a rich history spanning 51 years. As one of the largest and most comprehensive health supplement companies in the United States, it specializes in the development, production, and sale of vitamins, minerals, herbs, and other health, beauty, and weight loss products, offering a range of more than 1200 nutritional products. With Coenzyme Q10, Lutein, and Lycopene as its star products, all products are certified by the U.S. FDA. Puritan's Pride has expanded its product reach to more than 90 countries and regions globally, with a monthly production capacity of up to 2.15 billion pills since its establishment. SOURCE Puritan's Pride

21 Feb 2024

·www.prnewswire.com

New Study Publication Demonstrates Eye Health and Cognitive Benefits of Lutein and Zeaxanthin from Lutemax Kids

OmniActive Health Technologies Expands 'Lutein for Every Age' educational initiative with focus on children's nutrition and supplementation BRIDGEWATER, N.J. and MUMBAI, India , Feb. 21, 2024 /PRNewswire/ -- Six in ten parents regularly worry about their child's eye health, prioritizing it above other well-being needs; however, they are unfamiliar with ways to support it. This finding is according to a OmniActive Health Technologies U.S. parent survey for its "Lutein for Every Age" educational initiative, which focuses on raising awareness of early and consistent lutein and zeaxanthin intake to help support eye, cognitive, and general health throughout life. Continue Reading Lutemax OmniActive today unveils groundbreaking results from a first-of-its-kind completed supplementation study targeting children 5-12 years of age, which was published in the journal Advances in Therapy. The publication revealed that Lutemax Kids resulted in significant improvements in aspects of vision performance and cognition. This further expands upon the company's earlier published research on adults, including the LAMA I & LAMA II (Lutein, Vision and Mental Acuity), and B.L.U.E. (Blue Light User Exposure) studies. "The study results demonstrated that Lutemax Kids supplementation contributes positively to aspects of eye health and cognitive performance in school-aged children, echoing the well-documented benefits observed in adults," said Dr. Billy Hammond, Professor (Behavioral and Brain Sciences Program) at the University of Georgia and lead researcher in the study. "From improved visual processing speed to eye strain that may result from digital device use, these outcomes serve as a foundation for tailored supplementation in children. It also emphasizes the potential to help meet specific needs of children during a critical developmental phase." Effects of Lutein and Zeaxanthin on Children's Eyes and Cognition The randomized, double-blind, placebo-controlled trial which spanned 180-day duration included 60 healthy male and female children ages 5-12. Participants were given either a daily dose of Lutemax Kids, containing 10 mg lutein and 2 mg zeaxanthin isomers in a gummy format, or placebo. The outcomes of the study supports that over time, supplementation with Lutemax Kids: Significantly increased blood levels of lutein and zeaxanthin Increased macular pigment optical density (MPOD) levels Increased visual processing speed Decreased eye strain and fatigue attributed to digital device usage Significantly improved aspects of cognitive health, including attention, focus, episodic memory, visuospatial memory, and visuospatial processing speed "Considering the amount of time kids are spending on screens, building a strong foundation for eye health through nutrition and supplementation from a young age is an important facet of maintaining a lifetime of well-being," said Dr. Joseph Allen, O.D., F.A.A.O., Dipl ABO and Vision Advisor for OmniActive's Lutein for Every Age. "This study is an important milestone for eye health and cognitive science, laying the groundwork for further understanding on how lutein and zeaxanthin can impact younger populations. It's exciting to see how nutrition can contribute positively to school-age children's eye health and cognitive performance." Opportunity to Raise Nutrition Awareness It has been documented that only 1 in 11 U.S. children eat the recommended servings of fruits and vegetables per day. And since the body cannot produce lutein and zeaxanthin, two major carotenoids found in the eye's macula, it is important to consume these nutrients through foods, such as kale and spinach, or by supplementing. To dig deeper into this topic for Lutein for Every Age, OmniActive's U.S. parent survey also suggests nutrition knowledge gaps around children's eye health. It was found that parents believe carrots are the best food to support vision (15%) when the American Academy of Ophthalmology (A.A.O.) recommends dark leafy greens because of the higher concentration of lutein. Unfortunately, only one in ten parents say their children take a vitamin or supplement daily. Lutemax Kids, a line extension of OmniActive's pioneering lutein and zeaxanthin extract brand Lutemax 2020, is a lower dose to help meet the nutritional needs of children. To learn more about how to support eye and brain health visit Lutemax.com/lfea and to find supplements that feature the Lutemax ingredient, visit Lutemax.com/where-to-buy. About OmniActive Established in 2005, OmniActive seeks to improve lives through innovative science and natural health solutions. OmniActive's product portfolio consists of scientifically validated, IP-protected, branded Specialty Actives and an extensive portfolio of natural Botanical Actives for global customers in the dietary supplement, functional food, and beverage markets. The company has offices in Mumbai, India, and Bridgewater, New Jersey. Media Contact Meredith Kish 373242@email4pr.com +1-973-202-4034 SOURCE Omniactive Health Technologies

Clinical Result

100 Deals associated with Lutein

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Age Related Macular Degeneration	Preclinical	US	University of Utah	01 May 2016
Uveitis	Preclinical	JP	Keio University	01 May 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CAREDS (ARVO2021)	Not Applicable	Age related disease lutein \| zeaxanthin	487	Lutein and zeaxanthin supplement use	ldjrwvweyf(vcfhdgbukp) = ldvgdzuxqr rjstldfekn (fsnkojkswd, 0.03) View more	Positive	01 Jun 2021
ARVO2016	Not Applicable	Corneal Endothelial Cell Loss	-	lutein-based dyes	(kcsbdzbqkl) = ljdyxiorzs wejmvtemuu (rozfhjngub ) View more	-	01 May 2016
				Phacodyne TM	(kcsbdzbqkl) = hhxibvnihe wejmvtemuu (rozfhjngub ) View more
ARVO2014	Not Applicable	sC5b-9	-	Lutein	blofgqacna(nncbmzhgdt) = vaqeqhorfz pdehfezkbm (pkswlkijtu )	Positive	01 Apr 2014
				Lutein	blofgqacna(nncbmzhgdt) = pwlmtubtqq pdehfezkbm (pkswlkijtu )
Pubmed \| J Matern Fetal Neonatal Med	Not Applicable	Retinopathy of Prematurity	-	Lutein and zeaxanthin	qngwuxylgw(oybeimwwsg) = dtvkwhsoda etcirhplhm (zknatabmbk )	Negative	01 May 2012
				Lutein (Placebo)	qngwuxylgw(oybeimwwsg) = buutamgczl etcirhplhm (zknatabmbk )
ARVO2009	Not Applicable	serum lutein \| macular pigment	-	Lutein	wmwfbsuthy(toesdlgfbk) = 0.0-0.39 txicqievsu (zhkkmmytac ) View more	-	01 Apr 2009
ARVO2008	Not Applicable	MPOD \| PERG	1	Lutein and Zeaxanthin	cwhxxrvxvd(telbfpodyr) = njhfkpedyg nuvhhkpend (vcnecpqiov )	-	01 May 2008
ARVO2005	Not Applicable	macular pigment optical density	3	Zeaxanthin 20mg	mlgrahgajd(okvwxkxinu) = jbvbywaxph sbkgmokaco (ukrkjtjres )	-	01 May 2005
				Lutein 30mg	mlgrahgajd(okvwxkxinu) = oqomacghha sbkgmokaco (ukrkjtjres )
LAST (ARVO2002)	Not Applicable	-	90	Lutein 10 mg	(bsnaglzsuf) = improvement in both treatment groups rzdbkvvczh (txrltlkmdq ) View more	-	01 Dec 2002
				Lutein/Antioxidants

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis